It has been proposed that inhibition of SGLT2 will reduce renal oxygen consumption and thereby contribute to the alleviation of renal tissue hypoxia, a key pathophysiological feature of AKI, and the development of chronic kidney disease [17–19]. Here, SLC5A2 is linked to chronic kidney disease.